185 related articles for article (PubMed ID: 37523014)
1. Evaluation of Encequidar as An Intestinal P-gp and BCRP Specific Inhibitor to Assess the Role of Intestinal P-gp and BCRP in Drug-Drug Interactions.
Chu J; Panfen E; Wang L; Marino A; Chen XQ; Fancher RM; Landage R; Patil O; Desai SD; Shah D; Xue Y; Sinz M; Shen H
Pharm Res; 2023 Nov; 40(11):2567-2584. PubMed ID: 37523014
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein-Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo.
Zhang Y; Shipkova PA; Warrack BM; Nelson DM; Wang L; Huo R; Chen J; Panfen E; Chen XQ; Fancher RM; Ruan Q; Christopher LJ; Xue Y; Sinz M; Shen H
Drug Metab Dispos; 2023 Jul; 51(7):851-861. PubMed ID: 37055191
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Assessment of Transporter-Mediated Drug-Drug Interactions Using a Probe Drug Cocktail in Cynomolgus Monkey.
Kosa RE; Lazzaro S; Bi YA; Tierney B; Gates D; Modi S; Costales C; Rodrigues AD; Tremaine LM; Varma MV
Drug Metab Dispos; 2018 Aug; 46(8):1179-1189. PubMed ID: 29880631
[TBL] [Abstract][Full Text] [Related]
4. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
5. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
6. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
7. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
[TBL] [Abstract][Full Text] [Related]
9. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Breast Cancer Resistance Protein (BCRP/ABCG2) on Drug Transport Across Caco-2 Cell Monolayers.
Kawahara I; Nishikawa S; Yamamoto A; Kono Y; Fujita T
Drug Metab Dispos; 2020 Jun; 48(6):491-498. PubMed ID: 32193356
[TBL] [Abstract][Full Text] [Related]
11. Maternal and Fetal Exposure to (-)-Δ
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2023 Mar; 51(3):269-275. PubMed ID: 36446608
[TBL] [Abstract][Full Text] [Related]
12. Black ginger extract and its active compound, 5,7-dimethoxyflavone, increase intestinal drug absorption via efflux drug transporter inhibitions.
Boonnop R; Meetam P; Siangjong L; Tuchinda P; Thongphasuk P; Soodvilai S; Soodvilai S
Drug Metab Pharmacokinet; 2023 Jun; 50():100500. PubMed ID: 36948091
[TBL] [Abstract][Full Text] [Related]
13. Comparative Hepatic and Intestinal Efflux Transport of Statins.
Deng F; Tuomi SK; Neuvonen M; Hirvensalo P; Kulju S; Wenzel C; Oswald S; Filppula AM; Niemi M
Drug Metab Dispos; 2021 Sep; 49(9):750-759. PubMed ID: 34162690
[TBL] [Abstract][Full Text] [Related]
14. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
[TBL] [Abstract][Full Text] [Related]
15. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
16. Using novobiocin as a specific inhibitor of breast cancer resistant protein to assess the role of transporter in the absorption and disposition of topotecan.
Su Y; Hu P; Lee SH; Sinko PJ
J Pharm Pharm Sci; 2007; 10(4):519-36. PubMed ID: 18261372
[TBL] [Abstract][Full Text] [Related]
17. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
18. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
Tournier N; Chevillard L; Megarbane B; Pirnay S; Scherrmann JM; Declèves X
Int J Neuropsychopharmacol; 2010 Aug; 13(7):905-15. PubMed ID: 19887017
[TBL] [Abstract][Full Text] [Related]
19. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
20. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.
Sodhi JK; Liu S; Benet LZ
Pharm Res; 2020 Sep; 37(10):208. PubMed ID: 32996065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
